The enrichment of tumor markers and activated platelets by PD-L1+ EVs, especially in the patients experiencing disease progression, suggests that EVs may participate in the escape from anticancer responses by competing with membrane PD-1 sites on T-cells, providing a barrier to protect tumors. This evidence concerns the gene CD274 and neoplasm.